Clinical Trial Update: The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update evaluating ruxolitinib for secondary acute myeloid leukemia evolving from myeloproliferative neoplasm across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia Evolving From Myeloproliferative Neoplasm

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder | Phase 1, Phase 2 | Status: UNKNOWN